ABSTRACT
The progressive increase in numbers of noninvasive cardiac imaging examinations broadens the spectrum of knowledge radiologists are expected to acquire in the management of drugs during CT coronary angiography (CTCA) and cardiac MR (CMR) to improve image quality for optimal visualization and assessment of the coronary arteries and adequate MR functional analysis. Aim of this review is to provide an overview on different class of drugs (nitrate, beta-blockers, ivabradine, anxiolytic, adenosine, dobutamine, atropine, dipyridamole and regadenoson) that can be used in CTCA and CMR, illustrating their main indications, contraindications, efficacy, mechanism of action, metabolism, safety, side effects or complications, and providing advices in their use.
Subject(s)
Cardiac Imaging Techniques , Computed Tomography Angiography/methods , Coronary Angiography/methods , Coronary Vessels/diagnostic imaging , Heart/diagnostic imaging , Magnetic Resonance Imaging/methods , Adenosine/administration & dosage , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/pharmacokinetics , Anti-Anxiety Agents/administration & dosage , Atropine/administration & dosage , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/adverse effects , Contraindications, Drug , Dipyridamole/administration & dosage , Dobutamine/administration & dosage , Humans , Ivabradine/administration & dosage , Ivabradine/adverse effects , Nitroglycerin/administration & dosage , Purines/administration & dosage , Purines/adverse effects , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Vasodilator Agents/administration & dosageABSTRACT
The world of cardiac imaging is proposing to physicians an ever-increasing spectrum of options and tools with the disadvantages of patients presently submitted to multiple, sequential, time-consuming, and costly diagnostic procedures and tests, sometimes with contradicting results. In the last two decades, the CCTA has evolved into a valuable diagnostic test in today's patient care, changing the official existing guidelines and clinical practice with a pivotal role to exclude significant CAD, in the referral of patients to the Cath-Lab, in the follow-up after coronary revascularization, and finally in the cardiovascular risk stratification.
